Market Overview

What A Week For MannKind

What A Week For MannKind
Related MNKD
The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
MannKind - Afrezza Scripts Still In 500s As Cash Balance Dwindles Down (Seeking Alpha)

MannKind Corporation (NASDAQ: MNKD) investors haven’t had much to cheer about lately, with the stock down more than 80 percent in the past three years. However, this week provided investors with a bit of optimism and traders with a huge opportunity for profits.

What Happened?

MannKind shares caught fire this week and are on track to close out the week up more than 140 percent. The move appears to have been triggered by the FDA approving an update to the company’s Afrezza prescribing information to include new study data indicating time-action profiles.

“These data articulate the rapid-acting nature of Afrezza to address post-prandial hyperglycemia, setting it apart from other mealtime options available to help patients maintain greater control over their blood glucose levels,” said Satish Garg, MD, MBBS, DM — Barbara Davis Center for Diabetes (BDC) – University of Colorado, in the company’s press release.

In addition to the positive fundamental news, the stock may have been subject to a short squeeze as well. According to Yahoo Finance, there are more than 21 million shares held short for an elevated short percent of float of 29.7.

Related Link: Collegium Rallies On 'Value-Based Contract' With Cigna; Here's What It Means

Not Everyone Surprised

This week’s huge move on massive volume took MannKind stock as high as $6.51 after it was trading as low as $0.67 back in May. While most Wall Street analysts had left MannKind for dead, Maxim Group initiated coverage with a Buy rating back in August.

“In the U.S., a conservative 5% share of the insulin market is a $350M opportunity," analyst Jason Kolbert said at the time. "At the current ~$120M market capitalization there is significant upside, in our view."

Levels To Watch

For now, technical traders will be watching the Dec. 2016 high of $4.34 as a possible support level on a pullback. However, If MannKind maintains its bullish momentum, it may not run into serious technical resistance until it hits its 2016 high of $11.20.

Joel Elconin contributed to this story.

Latest Ratings for MNKD

Jun 2018Maxim GroupTerminatesSell
Mar 2018Maxim GroupDowngradesHoldSell
Nov 2017Maxim GroupDowngradesBuyHold

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Technicals Top Stories Analyst Ratings Movers Trading Ideas General Best of Benzinga


Related Articles (MNKD)

View Comments and Join the Discussion!

NPD's Video Game Sales Data For September: What To Expect

Learn From Parliament's George Clinton And Nat Geo's Jason Silva At This Cannabis Tech Event